Cancer therapy developer Delcath Q3 revenue misses estimates

Delcath Systems

04/11/2025 13:08

Overview

Delcath Q3 revenue of $20.6 mln missed analyst expectations

Net income for Q3 was $0.8 mln, down from $1.9 mln last year

Company achieved positive adjusted EBITDA of $5.3 mln in Q3

Outlook

Delcath expects 2025 revenue between $83 mln and $85 mln

Company anticipates gross margins of 85% to 87% in 2025

Delcath projects positive adjusted EBITDA and cash flow each quarter of 2025

Result Drivers

HEPZATO KIT SALES - Revenue from HEPZATO KIT increased significantly to $19.3 mln from $10.0 mln in Q3 2024, driving overall revenue growth

R&D costs rise - R&D expenses were $8.0 million compared to $3.9 million last year

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$20.56 mln
$23.80 mln (7 Analysts)
Q3 EPS
$0.02
Q3 Net Income
$830,000
Q3 Gross Profit
$17.93 mln
Q3 Operating Expenses
$18.32 mln
Q3 Operating Income
-$388,000


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Delcath Systems Inc is $23.00, about 58.6% above its November 3 closing price of $9.52

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 36 three months ago

Press Release: ID:nBw7kWnsma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)